---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-269518"
form_type: "8-K"
ticker: "JANX"
cik: "0001817713"
company_name: "Janux Therapeutics, Inc."
filed_at: "2025-11-06T23:59:59+00:00"
generated_at: "2026-05-16T23:56:52.968556+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Janux Q3 2025 net loss narrows to $24.3M; cash at $989M; trial enrollment continues

## Summary
- Net loss of $24.3M improved from $28.1M in Q3 2024; R&D expense rose to $34.6M from $18.6M.
- Cash, equivalents & short-term investments totaled $989.0M, down from $1.03B at Dec 31, 2024.
- Enrollment ongoing in Phase 1 trials for JANX007 (mCRPC) and JANX008 (solid tumors); data updates expected Q4 2025.
- G&A expense fell to $10.6M vs $17.7M, last year included $9.5M stock-comp modification charge.

## SEC filing metadata
- accession: 0001193125-25-269518
- form_type: 8-K
- ticker: JANX
- cik: 0001817713
- company_name: Janux Therapeutics, Inc.
- filed_at: 2025-11-06T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1817713/000119312525269518/0001193125-25-269518-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1817713/000119312525269518/janx-20251106.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-269518
- JSON: https://secwatch.observer/filing/0001193125-25-269518.json
- Plain text: https://secwatch.observer/filing/0001193125-25-269518.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.